Health 2.0 Europe 2016

11 - 12 May 2016, Barcelona, Spain.
The 7th edition of Health 2.0 Europe is coming back to Barcelona for 3 full days of content that will explore European and international innovation in patient-provider communication, consumer health, data analytics and more.

Over 120 speakers and 600 attendees from around the world will reconvene to experience over 50 live product demos of innovative solutions that will shake up European health systems.

Confirmed keynotes already include:

  • Esther Dyson, Chairman, EDventure Holdings (USA)
  • Dr. Rafael Grossmann, Practicing surgeon and digital health pionneer (USA)
  • Damien Marmion, Global Head of Health, AXA (France)
  • Dr. Julio Mayol, Director of Innovation, Hospital Clinico San Carlos (Spain)
  • Pēteris Zilgalvis, Head of Unit, eHealth and Well Being – DG CONNECT, European Commission (Belgium)

Confirmed digital health champions also include:

  • Artem Andrianov, CEO, Cyntegrity (Germany)
  • Jani Ahonala, Co-founder & Chairman of the Board, Noona Healthcare, (Finland)
  • Dr. Tom Albert, Director - Health Strategy, AXA Krankenversicherung AG (Germany)
  • Jordina Arcal, Co-founder & COO, HealthApp (Spain)
  • Dr. Alexander Börve, Founder and CEO, FirstDerm.com (Sweden/USA)
  • Vas Bailey, Principal, Quid, Inc (USA)
  • Vedran Boškić, Healthcare ICT consultant, Parsek (Slovenia)
  • Joan Cornet, mHealth Director, Mobile World Capital (Spain)
  • Dustin DiTommaso, SVP, Behavior Change Design, Mad*Pow (USA)
  • Dr. Eduardo García Cruz, Urologist and Men’s Health Specialist, Barcelona Hospital Clinic (Spain)
  • Jorge Gonzalez, Managing Director, TICBioMed (Spain)
  • Jamison Feramisco, President and Co-Founder, Transfuse Solutions, Inc. (USA)
  • Tal Givoly, CEO and Co-founder, Medivizor (Israel)
  • Jorge Gonzalez Olalla, Managing Director, TICBioMed (Spain)
  • Min-Sung Sean Kim, Partner, XL Health (Germany)
  • Jörg Land, CEO, Tinnitracks (Germany)
  • Robert Milnes, CEO, Fertility Focus Limited (United Kingdom)
  • Peter Ohnemus, President & CEO, Dacadoo (Switzerland)
  • Pablo Pantaleoni, CEO, MedTep (Spain/USA)
  • Michael Seres, Founder, 11Health (United Kingdom)
  • Dr. Alexander Schachinger, CEO, EPatient RSD (Germany)
  • Mitchell Silva, Founder and CEO, Esperity (Belgium)
  • Marta Sjögren, Principal, Northzone (Sweden)
  • Pierre Socha, Investment Manager, Amadeus Capital Partners (United Kingdom)
  • Ed Stafford, Director of Informatics, Genomics England (United Kingdom)
  • Unity Stoakes, ‎Co-founder and President, StartUp Health (USA)
  • Donato Tramuto, President and CEO, Healthways and Founder, Health eVillages, (USA)
  • Salvador Vera, CEO, MYSPHERA (Spain)
  • Frank Westermann, Co-founder and CEO, mysugr (Austria)

A mix of visionary keynotes and interactive panel discussions, the 2016 edition will cover some of the following overarching themes:

  • Building blocks to a dynamic health innovation ecosystem
  • Data analytics: Structuring information for decision making
  • Solutions for hospitals and health professionals
  • Gamification and design strategies for behaviour change
  • Pharma 2.0: Going beyond the pill
  • Who will pay for Health 2.0?
  • Reimbursement - Players, trends, criteria and processes
  • The rise of consumer health interfaces
  • "SHUSH topics" and the infamous Unmentionables
  • Health 2.0 applications in emerging markets

For further information and to register, please visit:
https://goo.gl/IVCb3P

PS: Get 15% discount to attend Health 2.0 Europe 2016 using the code EHNEWS16

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]